Fresenius Medical Care AG & Co.

KGaA

COMPLETE OVERVIEW OF THE THIRD QUARTER AND FIRST NINE MONTHS 2022

October 30, 2022

Investor Relations

phone: +49 6172 609 2525

email: ir@fmc-ag.com

Content:

Statement of earnings page 2

Segment information page 3

Balance sheet page 4

Cash flow page 5

Revenue development page 6

Key metrics page 7

Quality data page 8

Reconciliation results excl. special items page 9

Outlook 2022 page 10

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those
described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory
reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks
and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius
Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Copyright by Fresenius Medical Care AG & Co. KGaA

Statement of earnings
in € million, except share data, unaudited Three months ended September 30, Nine months ended September 30,

Change Change
2022 2021 Change 2022 2021 Change
at cc at cc

Health Care Services 4,082 3,530 15.7% 2.4% 11,471 10,255 11.9% 1.9%
Health Care Products 1,014 911 11.2% 4.3% 2,930 2,717 7.9% 2.9%
Total revenue 5,096 4,441 14.7% 2.8% 14,401 12,972 11.0% 2.1%

Costs of revenue 3,737 3,174 17.8% 5.4% 10,438 9,214 13.3% 4.0%
Gross profit 1,359 1,267 7.2% -3.7% 3,963 3,758 5.5% -2.6%
Selling, general and administrative 990 731 35.3% 21.7% 2,830 2,273 24.5% 15.2%
Research and development 61 52 17.4% 10.0% 167 153 8.9% 3.4%
Income from equity method investees (17) (21) -17.1% -17.7% (47) (71) -33.6% -33.8%
Remeasurement Gain From InterWell Health (147) — (147) —
Operating income 472 505 -6.5% -16.5% 1,160 1,403 -17.3% -24.4%
1
Operating income excl. special items 470 513 -8.5% -17.6% 1,322 1,423 -7.1% -14.4%

Interest income (16) (16) 3.0% -15.6% (43) (45) -4.2% -5.8%
Interest expense 92 84 10.1% -3.6% 260 259 0.6% -7.1%
Interest expense, net 76 68 11.8% -0.8% 217 214 1.6% -7.4%
Income before taxes 396 437 -9.4% -19.0% 943 1,189 -20.7% -27.5%
Income tax expense 112 105 6.9% -3.7% 242 274 -11.8% -18.9%
Net income 284 332 -14.6% -23.8% 701 915 -23.4% -30.0%
Net income attributable to noncontrolling interests 54 59 -9.2% -22.5% 166 174 -4.9% -15.3%
Net income attributable to shareholders of FMC AG &
230 273 -15.7% -24.1% 535 741 -27.8% -33.5%
Co. KGaA
Net income attributable to shareholders of FMC AG & Co.
231 280 -17.2% -24.6% 660 756 -12.6% -18.5%
KGaA excl. special items 1

Operating income 472 505 -6.5% -16.5% 1,160 1,403 -17.3% -24.4%
Depreciation, amortization and impairment loss 502 402 24.6% 11.3% 1,344 1,187 13.2% 3.9%
EBITDA 974 907 7.3% -4.2% 2,504 2,590 -3.3% -11.5%

Weighted average number of shares 293,413,449 292,986,093 293,190,145 292,926,425

Basic earnings per share €0.78 €0.93 -15.9% -24.2% €1.82 €2.53 -27.9% -33.6%
Basic earnings per ADS €0.39 €0.47 -15.9% -24.2% €0.91 €1.26 -27.9% -33.6%

In percent of revenue
Operating income margin 9.3% 11.4% 8.1% 10.8%
1
Operating income margin excl. special items 9.2% 11.6% 9.2% 11.0%
EBITDA margin 19.1% 20.4% 17.4% 20.0%
1
For a reconciliation of special items, please refer to the table on page 9.

Statement of earnings page 2 of 10 October 30, 2022

Segment information
unaudited Three months ended September 30, Nine months ended September 30,

Change Change
2022 2021 Change 2022 2021 Change
at cc at cc

Total
Revenue in € million 5,096 4,441 14.7% 2.8% 14,401 12,972 11.0% 2.1%
Operating income in € million 472 505 -6.5% -16.5% 1,160 1,403 -17.3% -24.4%
Operating income margin 9.3% 11.4% 8.1% 10.8%
Days sales outstanding (DSO) 69 59
Employees (full-time equivalents) 122,758 123,528

North America
Revenue in € million 3,556 3,080 15.5% -1.0% 10,021 8,931 12.2% -0.2%
Operating income in € million 469 446 5.1% -8.0% 1,113 1,242 -10.4% -19.8%
Operating income margin 13.2% 14.5% 11.1% 13.9%
Days sales outstanding (DSO) 55 38

EMEA
Revenue in € million 720 671 7.3% 8.3% 2,121 2,033 4.3% 5.9%
Operating income in € million 48 79 -39.6% -40.9% 169 232 -27.3% -26.1%
Operating income margin 6.6% 11.7% 8.0% 11.4%
Days sales outstanding (DSO) 89 89

Asia-Pacific
Revenue in € million 565 501 12.7% 7.2% 1,588 1,458 8.9% 4.3%
Operating income in € million 85 86 -1.3% -2.0% 255 256 -0.3% -1.2%
Operating income margin 15.1% 17.2% 16.1% 17.5%
Days sales outstanding (DSO) 102 104

Latin America
Revenue in € million 243 178 36.4% 36.3% 633 508 24.7% 23.2%
Operating income in € million 11 4 149.7% 130.3% 16 14 16.5% -6.5%
Operating income margin 4.5% 2.4% 2.5% 2.7%
Days sales outstanding (DSO) 116 143

Corporate
Revenue in € million 12 11 7.9% -1.4% 38 42 -7.8% -13.6%
Operating income in € million (141) (110) 27.1% 17.6% (393) (341) 15.4% 9.5%

cc = constant currency. Changes in revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items include the impact of changes in foreign currency
exchange rates. We calculate these non-IFRS financial measures at constant exchange rates to show changes in our revenue, operating income, net income attributable to shareholders of FMC AG
& Co. KGaA and other items without giving effect to period-to-period currency fluctuations. Under IFRS, amounts received in local (non-euro) currency are translated into euro at the average
exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period using the prior period
exchange rates versus the prior period. The single quarter results are calculated as the variance between the current year-to-date results less the preceding quarter’s year-to-date which makes the
single quarter subject to further foreign exchange fluctuation. This resulting percentage is a non-IFRS measure referring to a change as a percentage at constant currency. These currency-adjusted
financial measures are identifiable by the designated term "Constant Currency".

Segment information page 3 of 10 October 30, 2022

Balance sheet
in € million, except for net leverage ratio, unaudited September 30 December 31

2022 2021

Assets
Current assets 8,513 7,967
Goodwill and intangible assets 18,791 15,821
Right of use assets 4,571 4,316
Other non-current assets 6,531 6,263
Total assets 38,406 34,367

Liabilities and equity

Current liabilities 6,357 7,258
Non-current liabilities 15,314 13,130
Total equity 16,735 13,979
Total liabilities and equity 38,406 34,367

Equity/assets ratio 44% 41%

Debt and lease liabilities

Short-term debt from unrelated parties 544 1,178
Short-term debt from related parties 39 78
Current portion of long-term debt 58 668
Current portion of lease liabilities from unrelated parties 710 640
Current portion of lease liabilities from related parties 22 21
Long-term debt, less current portion 8,068 6,647
Lease liabilities from unrelated parties, less current portion 4,262 3,990
Lease liabilities from related parties, less current portion 83 98
Total debt and lease liabilities 13,786 13,320
Minus: Cash and cash equivalents (1,114) (1,482)
Total net debt and lease liabilities 12,672 11,838

Reconciliation of annualized adjusted EBITDA and net leverage

ratio to the most directly comparable IFRS financial measures
Net income 1,004 1,219
Income tax expense 321 353
Interest income (71) (73)
Interest expense 355 353
Depreciation and amortization 1,693 1,586
Adjustments1 214 125
Annualized adjusted EBITDA 3,516 3,563

Net leverage ratio 3.6 3.3

1
Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in
the Syndicated Credit Facility (2022: -€27 M; 2021: €13 M), non-cash charges, primarily related to pension expense (2022:
€52 M; 2021: €49 M), impairment loss (2022: €88 M; 2021: €38 M) and special items, including costs related to the FME25
Program (2022: €106 M; 2021: €25 M), Net Gain Related to InterWell Health (2022: -€113 M), Humacyte Investment
Remeasurement (2022: €79 M), Hyperinflation in Turkiye (2022: €6 M) and the Impacts Related to the War in Ukraine (2022:
€23 M).

Balance sheet page 4 of 10 October 30, 2022

Cash flow statement

in € million, unaudited Three months ended September 30, Nine months ended September 30,

2022 2021 2022 2021

Operating activities
Net income 284 332 701 915
Depreciation, amortization and impairment loss 502 402 1,344 1,187
Change in working capital and other non-cash items (128) (42) (477) (282)
Net cash provided by (used in) operating activities 658 692 1,568 1,820
In percent of revenue 12.9% 15.6% 10.9% 14.0%

Investing activities
Purchases of property, plant and equipment and capitalized development
costs (160) (194) (495) (588)
Proceeds from sale of property, plant and equipment 3 13 9 27
Capital expenditures, net (157) (181) (486) (561)

Free cash flow 501 511 1,082 1,259

In percent of revenue 9.8% 11.5% 7.5% 9.7%

Acquisitions and investments, net of cash acquired, and purchases of

intangible assets 21 (142) (40) (270)
Investments in debt securities (6) 0 (92) (63)
Proceeds from divestitures 16 0 56 3
Proceeds from sale of debt securities 25 22 52 118
Free cash flow after investing activities 557 391 1,058 1,047

Cash flow page 5 of 10 October 30, 2022

Revenue development
Same
market
Change Organic treatment
in € million, unaudited 2022 2021 Change at cc growth growth1

Three months ended September 30,

Total revenue 5,096 4,441 14.7% 2.8% 2.1%
Health Care Services 4,082 3,530 15.7% 2.4% 1.6% -1.3%
Health Care Products 1,014 911 11.2% 4.3% 4.3%

North America 3,556 3,080 15.5% -1.0% -1.9%

2
Health Care Services 3,269 2,810 16.3% -0.3% -1.3% -2.4%
Health Care Products 287 270 6.4% -9.0% -9.0%

EMEA 720 671 7.3% 8.3% 8.2%

Health Care Services 377 346 8.7% 8.5% 8.4% 0.5%
Health Care Products 343 325 5.8% 8.1% 8.0%

Asia-Pacific 565 501 12.7% 7.2% 7.0%

Health Care Services 256 239 7.2% 4.9% 4.6% 2.5%
Health Care Products 309 262 17.8% 9.2% 9.2%

Latin America 243 178 36.4% 36.3% 37.1%

Health Care Services 173 126 37.1% 41.6% 42.8% -0.7%
Health Care Products 70 52 34.6% 23.4% 23.4%

Corporate 12 11 7.9% -1.4%

Health Care Services 7 9 -6.2% -18.9%
Health Care Products 5 2 41.3% 40.0%

Nine months ended September 30,

Total revenue 14,401 12,972 11.0% 2.1% 1.3%
Health Care Services 11,471 10,255 11.9% 1.9% 0.9% -1.4%
Health Care Products 2,930 2,717 7.9% 2.9% 2.9%

North America 10,021 8,931 12.2% -0.2% -1.3%

2
Health Care Services 9,184 8,148 12.7% 0.2% -0.9% -2.3%
Health Care Products 837 783 6.8% -5.0% -5.0%

EMEA 2,121 2,033 4.3% 5.9% 5.6%

Health Care Services 1,083 1,020 6.2% 6.7% 6.2% -0.1%
Health Care Products 1,038 1,013 2.4% 5.0% 4.9%

Asia-Pacific 1,588 1,458 8.9% 4.3% 4.1%

Health Care Services 730 694 5.1% 3.3% 2.8% 2.2%
Health Care Products 858 764 12.4% 5.3% 5.3%

Latin America 633 508 24.7% 23.2% 23.7%

Health Care Services 452 364 24.1% 25.8% 26.6% -1.4%
Health Care Products 181 144 26.3% 16.5% 16.5%

Corporate 38 42 -7.8% -13.6%

Health Care Services 22 29 -21.5% -29.6%
Health Care Products 16 13 24.6% 24.1%
1
Same market treatment growth = organic growth less price effects
2
U.S. (excl. Mexico), same market treatment growth North America: -2.5% for the three months and -2.3% for the nine months ended September
30, 2022.

Revenue development page 6 of 10 October 30, 2022

Key metrics Dialysis Care Services
unaudited Nine months ended September 30, 2022

Growth Growth Growth

Clinics De novos Patients Treatments
in % in % in %

Total 4,153 0% 35 344,593 0% 39,152,144 -1%

North America 2,699 1% 20 208,275 -1% 23,816,538 -1%
EMEA 814 0% 5 66,293 1% 7,428,380 1%
Asia-Pacific 397 -2% 8 33,800 1% 3,613,229 1%
Latin America 243 -1% 2 36,225 -1% 4,293,997 -3%

Key metrics page 7 of 10 October 30, 2022

Quality data1
in % of patients North America EMEA Latin America Asia-Pacific

Q3 2022 Q3 2021 Q3 2022 Q3 2021 Q3 2022 Q3 2021 Q3 2022 Q3 2021

Kt/V ≥ 1.2 98 97 93 93 93 94 95 94
Hemoglobin = 10-12 g/dl 71 71 81 81 48 48 52 51
Calcium = 8.4-10.2 mg/dl 84 83 81 80 78 74 72 70
Albumin ≥ 3.5 g/dl 85 81 89 89 92 90 89 88
Phosphate ≤ 5.5 mg/dl 59 57 78 78 81 76 69 67
Patients without catheter
(after 90 days) 76 78 76 77 77 78 79 80

in days
Days in hospital per patient year
(global basis) 10.7 11.3 (Q3 2021)

1
Definitions cf. Annual Report 2021, Section "Non-Financial Group Report"

Quality data page 8 of 10 October 30, 2022

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures for comparability with the Company´s outlook

Results excl. special items

Net Gain
Related to Humacyte Results 2022 Results 2021
Results InterWell Investment Hyperinflation excl. special Results excl. special Change
in € million, except share data, unaudited 2022 FME25 Program Health1 Remeasurement Ukraine War2 in Turkiye items 2021 FME25 program items Change at cc

Three months ended September 30,

Total revenue 5,096 5,096 4,441 4,441 14.7% 2.8%

EBITDA 974 52 (113) 1 0 0 914 907 9 916 -0.3% -10.6%

Total operating income 472 53 (56) 1 0 0 470 505 8 513 -8.5% -17.6%
North America 469 16 (56) 1 — — 430 446 3 449 -4.3% -16.7%
EMEA 48 9 — — 0 1 58 79 — 79 -26.8% -25.1%
Asia-Pacific 85 0 — — — — 85 86 — 86 -1.3% -2.0%
Latin America 11 3 — — — — 14 4 — 4 219.3% 191.6%
Corporate (141) 25 — — — (1) (117) (110) 5 (105) 10.8% 2.2%

Interest expense, net 76 76 68 68 11.8% -0.8%

Income tax expense 112 15 (18) 0 0 — 109 105 1 106 1.8% -7.6%

Net income attributable to noncontrolling

interests 54 54 59 59 -9.2% -22.5%

3
Net income 230 38 (38) 1 0 0 231 273 7 280 -17.2% -24.6%

Basic earnings per share €0.78 €0.13 €(0.13) €0.01 €0.00 €0.00 €0.79 €0.93 €0.02 €0.95 -17.3% -24.7%

Nine months ended September 30,

Total revenue 14,401 14,401 12,972 12,972 11.0% 2.1%

EBITDA 2,504 101 (113) 79 23 6 2,600 2,590 20 2,610 -0.4% -8.3%

Total operating income 1,160 109 (56) 79 24 6 1,322 1,403 20 1,423 -7.1% -14.4%
North America 1,113 36 (56) 79 — — 1,172 1,242 6 1,248 -6.1% -16.0%
EMEA 169 14 — — 24 7 214 232 — 232 -7.9% -4.0%
Asia-Pacific 255 0 — — — — 255 256 — 256 -0.2% -1.1%
Latin America 16 3 — — — — 19 14 — 14 38.9% 13.2%
Corporate (393) 56 — — — (1) (338) (341) 14 (327) 3.5% -1.8%

Interest expense, net 217 217 214 214 1.6% -7.4%

Income tax expense 242 31 (18) 21 3 — 279 274 5 279 -0.3% -8.0%

Net income attributable to noncontrolling

interests 166 166 174 174 -4.9% -15.3%

Net income3 535 78 (38) 58 21 6 660 741 15 756 -12.6% -18.5%

Basic earnings per share €1.82 €0.27 €(0.13) €0.20 €0.07 €0.02 €2.25 €2.53 €0.05 €2.58 -12.7% -18.6%

1
Remeasurement gain of the investment, prior to the transaction, in InterWell Health LLC, the impairment of certain long-lived assets belonging to Acumen Physician Solutions, LLC which was transferred to InterWell Health as part of the transaction and certain
transaction-related costs.
2
Bad debt expense in Russia and Ukraine and accruals for certain risks associated with allowances on inventories related to the Ukraine War.
3
Attributable to shareholders of FMC AG & Co. KGaA

Reconciliation results excl. special items page 9 of 10 October 30, 2022

Outlook 2022
Revised Outlook 2022 Previous Outlook 2022
Spalte1 Results 2021 (at Constant Currency, except for ROIC) (at Constant Currency, except for ROIC)

Revenue1 €17,619 M growth: low-single-digit percentage rate growth: low-single-digit percentage rate
1
Revenue growth at Constant Currency growth: low-single-digit percentage rate growth: low-single-digit percentage rate
1
Operating income €1,915 M decline: mid-teens to high-teens percentage rate decline: around mid-teens percentage rate
1, 2
Net income €1,018 M decline: high-teens to mid-twenties percentage rate decline: around high-teens percentage rate
2 1
Net income growth at Constant Currency decline: high-teens to mid-twenties percentage rate decline: around high-teens percentage rate
1
ROIC 5.1% around 4.0% ≥ 4.0%

1
Outlook 2022 is based on the assumptions outlined in the presentation for the third quarter and first nine months 2022 and excludes special items. Special items include further costs
related to the FME25 Program, net gain related to InterWell Health, Humacyte investment remeasurement, hyperinflation in Turkiye, the impacts related to the war in Ukraine and other
effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. The growth rates are based on the results 2021
excluding the costs related to the FME25 Program (€63 M for operating income and €49 M for net income).
2
Net income attributable to shareholders of FMC AG & Co. KGaA.

Outlook 2022 page 10 of 10 October 30, 2022